Lundbeck's star drug Lexapro rapidly gains US market share  

In Q3 2002 Lundbeck's US partner Forest Labs racked up USD 80 million in sales of Lexapro, which has already claimed an 8% market share

Lundbeck's US partner Forest Labs is having considerable success selling the new generation SSRI antidepressant Lexapro (escitalopram), reports national daily newspaper Jyllands-Posten. In Q3 2002 Forest Labs racked up USD 80 million in sales of Lexapro, which in a matter of months has grabbed an 8% slice of the US antidepressant market. Lundbeck's established antidepressant Celexa (citalopram) already has a 13% market share.


According to the US investment bank J P Morgan Chase, combined US sales of Lundbeck's antidepressant drugs are forecast to approach DKK 20 billion (USD 2.8 billion) over the next 4 years, with Lexapro accounting for DKK 18.4 billion (USD 2.6 billion) of the prospective total. Lundbeck Group's 2002 turnover is expected to be around DKK 10 billion (USD 1.4 billion), including estimated royalty payments from Forest Labs.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×